NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Wave Life Sciences, Inc. (WVE) Stock Analysis

Wave Life Sciences, Inc. (WVE) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

WVE

$4.86

+$0.16 (+3.40%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare WVE with… →

WVE Key Statistics

As of Sep 4, 2026
Trading
Open
$4.71
Previous Close
$4.70
Day's Range
4.65–4.89
52-Week Range
4.65–21.73
Volume
3.03M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−1.30
Valuation
Market Cap
$957.65M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
14.65
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.08
Financials (FY)
Revenue (FY)
$42.73M−60.55%
Net Income (FY)
−$204.38M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
197.05M
1-Year Return
−40.59%
Dividend and dates
Earnings Date
November 9, 2026
Avg Volume
3.13M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

WVE Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−71.41%
2025+37.43%
2024+144.95%
2023−27.86%
2022+122.93%
2021−60.10%
2020−1.87%
2019−80.92%
2018+19.77%
2017+34.23%
2016 (partial year)+34.17%

As of September 4, 2026.

WVE Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$42.73M−$204.38M−478.3%
2024$108.30M−$97.01M−89.6%
2023$113.31M−$57.51M−50.8%
2022$3.65M−$161.82M−4434.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$42.73M—−$215.38M−$204.38M−478.3%
2024$108.30M—−$110.40M−$97.01M−89.6%
2023$113.31M—−$68.00M−$57.51M−50.8%
2022$3.65M—−$162.72M−$161.82M−4434.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

WVE Valuation vs Biotechnology Median

Median of 656 stocks
MetricWVEBiotechnology medianvs median
P/S ratio14.6515.264% below
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 14 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Wave Life Sciences, Inc. (WVE) is capitalised at $957.65M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 317 employees.

Over the past 52 weeks the price has ranged from $4.65 to $21.73. WVE last closed at $4.86 on September 4, 2026. That is +$0.16 (+3.40%) against the previous close. The latest close sits 4.52% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $42.73M. Against the prior fiscal year total of $108.30M, that is a change of −60.55%. The same year closed with a net loss of $204.38M. The reported profit margin is 0%. Trailing earnings per share are −1.08.

Across the 4 fiscal years on file, revenue moves from $3.65M in 2022 to $42.73M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 14.65 times revenue. On price-to-sales that is 4.02% below the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned −40.59%. Measured over 10 years, that is −15.10% a year compounded. Beta against the wider market is reported at −1.3. Daily returns over the trailing 10 years annualize to a volatility of 98.82%.

Growth & Income

The record shows no dividend for WVE.

Across the complete calendar years on file, 2024 returned +144.95% and 2019 returned −80.92%. Of the 9 complete calendar years on file, 5 finished higher. So far in 2026 the price is −71.41%.

Peer Comparison

Wave Life Sciences, Inc. (WVE) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Wave Life Sciences, Inc. WVE $957.65M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Wave Life Sciences, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Wave Life Sciences, Inc.

Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006), and PNPLA3 I148M liver disease (WVE-008) programs; and clinical programs for Duchenne muscular dystrophy and Huntington's disease, as well as various preclinical programs utilizing its RNA medicines platform. Wave Life Sciences, Inc. was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Visit website →